Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pacts In Medtech, July/August 2016

Executive Summary

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, this new bimonthly Pacts In Medtech column pulls up notable technology alliances, R&D partnerships and commercial collaborations. This month we highlight deals announced in July and August 2016.

You may also be interested in...



New GSK-Verily JV Aims For Smart, 'Grain Of Rice' Neuromod Tech

Galvani Bioelectronics, the new joint venture between Google’s health-care spinoff Verily and drug giant GSK, will develop a new generation of "bioelectronic medicines" – neuromodulating therapies to treat a wide range of chronic diseases. Brian Otis, CTO of Verily, tells Medtech Insight how the devices that will come out of Galvani differ from existing neuromodulation technologies.

Financing Quarterly Statistics, Q3 2020

During Q3, biopharmas brought in an aggregate $36.6bn in financing and device company fundraising totaled $3.3bn; while in vitro diagnostic firms and research tools players raised $3.4bn.

Deals In Depth: September 2020

Seattle Genetics and Merck penned an agreement to globally develop and commercialize (on a co-exclusive basis) Seattle Genetics’ ladiratuzumab vedotin, an investigational antibody-drug conjugate in Phase II trials for breast cancer and other solid tumors. The deal has a potential value of over $4bn. While Gilead Sciences entered into a definitive agreement to acquire Immunomedics Inc. for $88 per share in cash, or approximately $21bn. The transaction is expected to close in Q4 2020. Financing reached $14.6bn in biopharma, $824m in devices and $1.9bn in diagnostics.

Topics

Related Companies

UsernamePublicRestriction

Register

LL1134211

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel